Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.

The Journal of biological chemistry - 28 Jan 2005

Winkler David G, Sutherland May S Kung, Ojala Ethan, Turcott Eileen, Geoghegan James C, Shpektor Diana, Skonier John E, Yu Changpu, Latham John A

Abstract excerpt

High bone mass diseases are caused both by activating mutations in the Wnt pathway and by loss of SOST, a bone morphogenetic protein (BMP) antagonist, leading to the activation of BMP signaling. Given the phenotypic similarity between mutations that activate these signaling pathways, it seems lik...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkaline Phosphatase
Share to beta Catenin
Share to Bone Morphogenetic Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred C3H

Share to Osteoblasts

Share to Wnt Proteins

Share to Wnt3 Protein

Share to Wnt3A Protein

Source

Identifiers

PMID: 15545262
DOI: 10.1074/jbc.M400524200

Genes

SOST

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15545262-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.PMID 15545262Read ↗

Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt SignalingSemantic proximity Read ↗

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.Semantic proximity Read ↗

SOST/sclerostin, an osteocyte-derived negative regulator of bone formationSemantic proximity Read ↗

Sclerostin: Current Knowledge and Future PerspectivesSemantic proximity Read ↗

Osteocyte control of bone formation via sclerostin, a novel BMP antagonistSemantic proximity Read ↗

Sclerostin: a novel target for intervention in the treatment of osteoporosis.Semantic proximity Read ↗

The Therapeutic Potential of the Wnt Signaling Pathway in Bone DisordersSemantic proximity Read ↗

Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.Semantic proximity Read ↗

Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cellsSemantic proximity Read ↗

The role of the Wnt signaling pathway in osteoblast commitment and differentiation.Semantic proximity Read ↗

Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 elementSemantic proximity Read ↗

SclerostinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.